Fidelity Investments’s Trevi Therapeutics TRVI Stock Holding History

Fidelity Investments’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234M	Buy	12,562,839 +4,524,778	+56%	+$65.8M	0.01%	865
2026 Q1	$95.9M	Buy	8,038,061 +1,538,052	+24%	+$17.2M	0.01%	1199
2025 Q4	$81.4M	Buy	6,500,009 +3,200,118	+97%	+$37M	﹤0.01%	1261
2025 Q3	$30.2M	Buy	3,299,891 +2,931,362	+795%	+$22M	﹤0.01%	1625
2025 Q2	$2.02M	Buy	368,529 +362,528	+6,041%	+$2.26M	﹤0.01%	2485
2025 Q1	$37.7K	Buy	6,001 +1,641	+38%	+$7.83K	﹤0.01%	3978
2024 Q4	$18K	Buy	4,360 +665	+18%	+$2.13K	﹤0.01%	4224
2024 Q3	$12.3K	Buy	3,695 +91	+3%	+$270	﹤0.01%	4361
2024 Q2	$10.7K	Buy	3,604 +69	+2%	+$192	﹤0.01%	4308
2024 Q1	$12.2K	Buy	3,535 +24	+0.7%	+$54	﹤0.01%	4197
2023 Q4	$4.71K	Buy	3,511 +1,931	+122%	+$2.92K	﹤0.01%	4465
2023 Q3	$3.44K	Buy	1,580 +694	+78%	+$1.57K	﹤0.01%	4414
2023 Q2	$2.12K	Buy	+886	New	+$2.23K	﹤0.01%	4576
2022 Q4	–	Sell	-1,560,125	Closed	-$2.4M	–	5595
2022 Q3	$2.4M	Buy	1,560,125 +1,476,900	+1,775%	+$4.84M	﹤0.01%	2385
2022 Q2	$234K	Buy	+83,225	New	+$204K	﹤0.01%	3090
2021 Q2	–	Sell	-576,500	Closed	-$1.57M	–	4876
2021 Q1	$1.57M	Hold	576,500	–	–	﹤0.01%	2509
2020 Q4	$1.4M	Sell	576,500 -216,200	-27%	-$700K	﹤0.01%	2468
2020 Q3	$3.19M	Hold	792,700	–	–	﹤0.01%	2190
2020 Q2	$5.22M	Hold	792,700	–	–	﹤0.01%	2036
2020 Q1	$2.61M	Hold	792,700	–	–	﹤0.01%	2125
2019 Q4	$2.97M	Hold	792,700	–	–	﹤0.01%	2164
2019 Q3	$3.57M	Hold	792,700	–	–	﹤0.01%	2135
2019 Q2	$5.95M	Buy	+792,700	New	+$6.83M	﹤0.01%	2044

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fidelity Investments's TRVI Position: Q2 2026 in Review

Fidelity Investments increased its Trevi Therapeutics (TRVI) stake by 56% in Q2 2026, buying an estimated $65.8M and bringing the position to 12,562,839 shares worth $234M. The position accounts for 0.01% of the portfolio, ranked #865.

Fidelity Investments first reported a position in TRVI in Q2 2019 and has held it in 23 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Fidelity Investments held 12,562,839 shares of Trevi Therapeutics worth $234M as of Q2 2026.
Fidelity Investments bought 4,524,778 Trevi Therapeutics shares in Q2 2026, an estimated $65.8M.
Trevi Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #865 holding.
Fidelity Investments first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 23 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.